Cargando…

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

We previously identified matrix metalloproteinase 2 (MMP2) and MMP9 plasma levels as candidate biomarkers of bevacizumab activity in patients with recurrent glioblastoma. The aim of this study was to assess the predictive value of MMP2 and MMP9 in a randomized phase III trial in patients with newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiguet-Jiglaire, Carine, Boissonneau, Sebastien, Denicolai, Emilie, Hein, Victoria, Lasseur, Romain, Garcia, Josep, Romain, Sylvie, Appay, Romain, Graillon, Thomas, Mason, Warren, Carpentier, Antoine F., Brandes, Alba A., Ouafik, L.’Houcine, Wick, Wolfgang, Baaziz, Ania, Gigan, Julien P., Argüello, Rafael J., Figarella-Branger, Dominique, Chinot, Olivier, Tabouret, Emeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722051/
https://www.ncbi.nlm.nih.gov/pubmed/34980260
http://dx.doi.org/10.1186/s40478-021-01305-4
_version_ 1784625450990960640
author Jiguet-Jiglaire, Carine
Boissonneau, Sebastien
Denicolai, Emilie
Hein, Victoria
Lasseur, Romain
Garcia, Josep
Romain, Sylvie
Appay, Romain
Graillon, Thomas
Mason, Warren
Carpentier, Antoine F.
Brandes, Alba A.
Ouafik, L.’Houcine
Wick, Wolfgang
Baaziz, Ania
Gigan, Julien P.
Argüello, Rafael J.
Figarella-Branger, Dominique
Chinot, Olivier
Tabouret, Emeline
author_facet Jiguet-Jiglaire, Carine
Boissonneau, Sebastien
Denicolai, Emilie
Hein, Victoria
Lasseur, Romain
Garcia, Josep
Romain, Sylvie
Appay, Romain
Graillon, Thomas
Mason, Warren
Carpentier, Antoine F.
Brandes, Alba A.
Ouafik, L.’Houcine
Wick, Wolfgang
Baaziz, Ania
Gigan, Julien P.
Argüello, Rafael J.
Figarella-Branger, Dominique
Chinot, Olivier
Tabouret, Emeline
author_sort Jiguet-Jiglaire, Carine
collection PubMed
description We previously identified matrix metalloproteinase 2 (MMP2) and MMP9 plasma levels as candidate biomarkers of bevacizumab activity in patients with recurrent glioblastoma. The aim of this study was to assess the predictive value of MMP2 and MMP9 in a randomized phase III trial in patients with newly diagnosed glioblastoma and to explore their tumor source. In this post hoc analysis of the AVAglio trial (AVAGlio/NCT00943826), plasma samples from 577 patients (bevacizumab, n = 283; placebo, n = 294) were analyzed for plasma MMP9 and MMP2 levels by enzyme-linked immunosorbent assay. A prospective local cohort of 38 patients with newly diagnosed glioblastoma was developed for analysis of tumor characteristics by magnetic resonance imaging and measurement of plasma and tumor levels of MMP9 and MMP2. In this AVAglio study, MMP9, but not MMP2, was correlated with bevacizumab efficacy. Patients with low MMP9 derived a significant 5.2-month overall survival (OS) benefit with bevacizumab (HR 0.51, 95% CI 0.34–0.76, p = 0.0009; median 13.6 vs. 18.8 months). In multivariate analysis, a significant interaction was seen between treatment and MMP9 (p = 0.03) for OS. In the local cohort, we showed that preoperative MMP9 plasma levels decreased after tumor resection and were correlated with tumor levels of MMP9 mRNA (p = 0.03). However, plasma MMP9 was not correlated with tumor size, invasive pattern, or angiogenesis. Using immunohistochemistry, we showed that MMP9 was expressed by inflammatory cells but not by tumor cells. After cell sorting, we showed that MMP9 was expressed by CD45+ immune cells. Finally, using flow cytometry, we showed that MMP9 was expressed by tumor-infiltrating neutrophils. In conclusion, circulating MMP9 is predictive of bevacizumab efficacy and is released by tumor-infiltrating neutrophils. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01305-4.
format Online
Article
Text
id pubmed-8722051
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87220512022-01-06 Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study Jiguet-Jiglaire, Carine Boissonneau, Sebastien Denicolai, Emilie Hein, Victoria Lasseur, Romain Garcia, Josep Romain, Sylvie Appay, Romain Graillon, Thomas Mason, Warren Carpentier, Antoine F. Brandes, Alba A. Ouafik, L.’Houcine Wick, Wolfgang Baaziz, Ania Gigan, Julien P. Argüello, Rafael J. Figarella-Branger, Dominique Chinot, Olivier Tabouret, Emeline Acta Neuropathol Commun Research We previously identified matrix metalloproteinase 2 (MMP2) and MMP9 plasma levels as candidate biomarkers of bevacizumab activity in patients with recurrent glioblastoma. The aim of this study was to assess the predictive value of MMP2 and MMP9 in a randomized phase III trial in patients with newly diagnosed glioblastoma and to explore their tumor source. In this post hoc analysis of the AVAglio trial (AVAGlio/NCT00943826), plasma samples from 577 patients (bevacizumab, n = 283; placebo, n = 294) were analyzed for plasma MMP9 and MMP2 levels by enzyme-linked immunosorbent assay. A prospective local cohort of 38 patients with newly diagnosed glioblastoma was developed for analysis of tumor characteristics by magnetic resonance imaging and measurement of plasma and tumor levels of MMP9 and MMP2. In this AVAglio study, MMP9, but not MMP2, was correlated with bevacizumab efficacy. Patients with low MMP9 derived a significant 5.2-month overall survival (OS) benefit with bevacizumab (HR 0.51, 95% CI 0.34–0.76, p = 0.0009; median 13.6 vs. 18.8 months). In multivariate analysis, a significant interaction was seen between treatment and MMP9 (p = 0.03) for OS. In the local cohort, we showed that preoperative MMP9 plasma levels decreased after tumor resection and were correlated with tumor levels of MMP9 mRNA (p = 0.03). However, plasma MMP9 was not correlated with tumor size, invasive pattern, or angiogenesis. Using immunohistochemistry, we showed that MMP9 was expressed by inflammatory cells but not by tumor cells. After cell sorting, we showed that MMP9 was expressed by CD45+ immune cells. Finally, using flow cytometry, we showed that MMP9 was expressed by tumor-infiltrating neutrophils. In conclusion, circulating MMP9 is predictive of bevacizumab efficacy and is released by tumor-infiltrating neutrophils. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01305-4. BioMed Central 2022-01-03 /pmc/articles/PMC8722051/ /pubmed/34980260 http://dx.doi.org/10.1186/s40478-021-01305-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiguet-Jiglaire, Carine
Boissonneau, Sebastien
Denicolai, Emilie
Hein, Victoria
Lasseur, Romain
Garcia, Josep
Romain, Sylvie
Appay, Romain
Graillon, Thomas
Mason, Warren
Carpentier, Antoine F.
Brandes, Alba A.
Ouafik, L.’Houcine
Wick, Wolfgang
Baaziz, Ania
Gigan, Julien P.
Argüello, Rafael J.
Figarella-Branger, Dominique
Chinot, Olivier
Tabouret, Emeline
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title_full Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title_fullStr Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title_full_unstemmed Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title_short Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
title_sort plasmatic mmp9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an avaglio ancillary study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722051/
https://www.ncbi.nlm.nih.gov/pubmed/34980260
http://dx.doi.org/10.1186/s40478-021-01305-4
work_keys_str_mv AT jiguetjiglairecarine plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT boissonneausebastien plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT denicolaiemilie plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT heinvictoria plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT lasseurromain plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT garciajosep plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT romainsylvie plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT appayromain plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT graillonthomas plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT masonwarren plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT carpentierantoinef plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT brandesalbaa plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT ouafiklhoucine plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT wickwolfgang plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT baazizania plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT giganjulienp plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT arguellorafaelj plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT figarellabrangerdominique plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT chinotolivier plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy
AT tabouretemeline plasmaticmmp9releasedfromtumorinfiltratingneutrophilsispredictiveforbevacizumabefficacyinglioblastomapatientsanavaglioancillarystudy